EXCLUSIVE: GT Biopharma Announces Potential New Indication for GTB-5550, A B7-H3-Targeted Natural Killer Cell Engager, For Multiple Myeloma; FDA Clearance Under Investigator Sponsored Trial Protocol
Benzinga Newsdesk 1 month ago
FDANewsExclusives
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant
- FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol
- Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding
- Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026
- Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027